Regeneron Pharmaceuticals Inc. buy Wells Fargo & Company
Summary
This prediction ended on 11.01.26 with a price of €683.00. With a performance of -1.53%, the BUY prediction by Wells_Fargo___Compan finished with a loss. Wells_Fargo___Compan has a follow-up prediction for Regeneron Pharmaceuticals Inc. where he still thinks Regeneron Pharmaceuticals Inc. is a Buy. A total of €3.48 was paid as dividends for this prediction. Wells_Fargo___Compan has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | -2.288% | -2.288% | 27.437% |
| iShares Core DAX® | 4.244% | 2.864% | 14.030% |
| iShares Nasdaq 100 | 4.890% | 2.814% | 32.707% |
| iShares Nikkei 225® | 9.397% | 7.826% | 48.296% |
| iShares S&P 500 | 3.528% | 1.950% | 25.247% |
Comments by Wells_Fargo___Compan for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
In the thread Trading Regeneron Pharmaceuticals Inc.
Current prediction by Wells_Fargo___Compan for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
30.04.25
30.04.26
20:49
Stopped prediction by Wells_Fargo___Compan for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
23.09.24
23.09.25
24.09.25
Regeneron Pharmaceuticals Inc.
02.08.24
02.08.25
03.08.25

